Free Trial
NASDAQ:ENVB

Enveric Biosciences (ENVB) Stock Price, News & Analysis

Enveric Biosciences logo
$1.15 -0.07 (-5.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.18 +0.04 (+3.04%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enveric Biosciences Stock (NASDAQ:ENVB)

Key Stats

Today's Range
$1.14
$1.23
50-Day Range
$1.17
$1.41
52-Week Range
$1.01
$8.95
Volume
162,856 shs
Average Volume
177,796 shs
Market Capitalization
$2.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Enveric Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ENVB MarketRank™: 

Enveric Biosciences scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Enveric Biosciences has received no research coverage in the past 90 days.

  • Read more about Enveric Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Enveric Biosciences are expected to grow in the coming year, from ($31.18) to ($21.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enveric Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enveric Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enveric Biosciences has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Enveric Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    9.98% of the float of Enveric Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Enveric Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enveric Biosciences has recently decreased by 20.63%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enveric Biosciences does not currently pay a dividend.

  • Dividend Growth

    Enveric Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.98% of the float of Enveric Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Enveric Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enveric Biosciences has recently decreased by 20.63%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 1.10% of the stock of Enveric Biosciences is held by insiders.

    • Percentage Held by Institutions

      Only 13.82% of the stock of Enveric Biosciences is held by institutions.

    • Read more about Enveric Biosciences' insider trading history.
    Receive ENVB Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter.

    ENVB Stock News Headlines

    Is America’s Everything Bubble About to Burst?
    On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushing America’s debt-to-GDP ratio to 175%. Top investors are warning of an epic bubble bursting soon. A free guide reveals how to shield your 401(k), savings, and portfolio before the collapse.
    See More Headlines

    ENVB Stock Analysis - Frequently Asked Questions

    Enveric Biosciences' stock was trading at $5.3760 at the beginning of 2025. Since then, ENVB stock has decreased by 78.6% and is now trading at $1.15.

    Enveric Biosciences, Inc. (NASDAQ:ENVB) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($1.22) earnings per share for the quarter, topping analysts' consensus estimates of ($3.45) by $2.23.

    Enveric Biosciences shares reverse split on Wednesday, January 29th 2025.The 1-15 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

    Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW) and Adobe (ADBE).

    Company Calendar

    Last Earnings
    5/14/2025
    Today
    8/01/2025
    Next Earnings (Estimated)
    8/11/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:ENVB
    CIK
    890821
    Employees
    20
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $10.00
    Low Price Target
    $10.00
    Potential Upside/Downside
    +729.9%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($38.38)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$9.57 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -250.28%
    Return on Assets
    -195.57%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.08
    Quick Ratio
    4.08

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $2.35 per share
    Price / Book
    0.51

    Miscellaneous

    Outstanding Shares
    2,472,000
    Free Float
    2,445,000
    Market Cap
    $2.98 million
    Optionable
    Not Optionable
    Beta
    0.54
    Elon Musk's Next Move Cover

    Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

    Get This Free Report

    This page (NASDAQ:ENVB) was last updated on 8/1/2025 by MarketBeat.com Staff
    From Our Partners